AMAL Therapeutics SA announces the appointment of Dr. Thomas Bogenrieder as Chief Clinical Officer

Geneva - 25 June 2020 - AMAL Therapeutics is very happy to welcome Thomas Bogenrieder, MD, PhD, as Chief Clinical Officer as of July 1, 2020. Thomas will join AMAL’s operations in Geneva. In this new role, he will focus on AMAL’s preclinical and clinical research activities especially in the vaccine and oncolytic virus areas, to support and promote BI’s Cancer Immunology and Immune Modulation unit and interface closely with BI’s Oncology Medical organization to advance and integrate the concepts in the overall portfolio.

View pdf Boehringer Ingelheim Acquires AMAL Therapeutics Significantly Enriching Its Cancer Immunology ... Season Greetings

Share this entry

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL:

OK